Related Experiment Videos
Activation of platelets in patients with chronic proliferative glomerulonephritis and the nephrotic syndrome
Insights
Platelet activation and aggregation are increased in chronic glomerulonephritis (CGN) patients, contributing to thrombotic risk. Antiplatelet drugs showed potential in reducing elevated beta-thromboglobulin (beta-TG) levels.
Area of Science:
- Nephrology
- Hematology
- Pathophysiology
Background:
- Chronic glomerulonephritis (CGN) is associated with potential thrombotic complications.
- Understanding platelet activation in CGN is crucial for managing disease progression and associated risks.
Purpose of the Study:
- To investigate platelet count, volume, aggregation, and plasma levels of beta-thromboglobulin (beta-TG) and platelet factor 4 (PF-4) in patients with CGN.
- To explore the relationship between these markers and disease severity, including progressive glomerular lesions and nephrotic syndrome.
- To assess the effect of antiplatelet drugs on plasma beta-TG levels.
Main Methods:
- Measured platelet count, volume, and aggregation (induced by ADP, adrenaline, collagen) in 54 CGN patients and normal subjects.
- Quantified plasma beta-TG and PF-4 levels.
- Correlated platelet parameters and plasma factors with creatinine clearance and disease status (nephrotic syndrome, progressive lesions).
- Administered antiplatelet drugs to a subset of patients and monitored beta-TG levels.
Main Results:
- CGN patients exhibited significantly higher platelet counts and aggregation responses compared to controls.
- Platelet aggregation was markedly increased in patients with progressive glomerular lesions.
- Plasma beta-TG and PF-4 levels were significantly elevated in CGN patients.
- A significant inverse correlation was observed between plasma beta-TG and creatinine clearance.
- Nephrotic patients had smaller platelet volume and elevated plasma beta-TG.
- Antiplatelet therapy led to a remarkable decrease in plasma beta-TG in most treated patients.
Conclusions:
- Platelet aggregation and release reactions are enhanced in patients with chronic glomerulonephritis.
- Activated platelets appear to play a significant role in the thrombotic tendency observed in the nephrotic syndrome.
- Therapeutic strategies targeting platelet activation may be beneficial in managing CGN patients.
Abstract:
Platelet count, volume and aggregation and plasma levels of beta-thromboglobulin (beta-TG) and platelet factor 4 (PF-4) were measured in 54 patients with chronic glomerulonephritis (CGN). Platelet count and platelet aggregation induced by ADP, adrenaline and collagen were significantly higher in the patients than in normal subjects, and platelet aggregation was markedly increased in the cases with progressive glomerular lesions. Plasma levels of beta-TG and PF-4 were significantly higher in the patients than in the normal subjects. There was a significant inverse correlation between plasma beta-TG and creatinine clearance. Nephrotic patients showed significantly smaller platelet volume and markedly elevated plasma beta-TG levels when compared to the controls. Plasma beta-TG decreased remarkably in 3 out of 4 patients with markedly increased beta-TG levels when they were given antiplatelet drugs. The results suggest that platelet aggregation and the release reaction were increased in patients with CGN. Activated platelets may be an important factor in the genesis of the thrombotic tendency in the nephrotic syndrome.